Citation Impact
Citing Papers
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
2018
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
2014 Standout
Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
2023 StandoutNobel
Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
2008 Standout
Phylogenetic variation and polymorphism at the Toll-like receptor 4 locus (TLR4)
2000 StandoutNobel
A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species
2014
The Brugada Syndrome: Is an Implantable Cardioverter Defibrillator the Only Therapeutic Option?
2002
Risk Stratification of Individuals with the Brugada Electrocardiogram: A Meta‐Analysis
2006
J-Point Elevation in Survivors of Primary Ventricular Fibrillation and Matched Control Subjects
2008
Sequential changes in the splanchnic circulation during continuous endotoxin infusion in sedated sheep: evidence for a selective increase of hepatic artery blood flow and loss of the hepatic arterial buffer response
1993
Phaeochromocytoma
2005 Standout
Quinidine Induced Electrocardiographic Normalization in Two Patients with Brugada Syndrome
2001
Hydroquinidine therapy in Brugada syndrome
2004
Perioperative management of pheochromocytoma
2002
Inflammatory response to cardiopulmonary bypass
1993 Standout
Genetic control of sodium channel function
2003
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Electrophysiologic investigation in Brugada syndrome. Yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats
2002
The Brugada Syndrome: Ionic Basis and Arrhythmia Mechanisms
2001
Clinical detection of LPS and animal models of endotoxemia
1993
Pathophysiology and Therapeutic Potential of Purinergic Signaling
2006
Electrophysiologic characteristics andimplications of induced ventricular fibrillationin symptomatic patients with brugada syndrome
2002
Significance of Inducible Ventricular Flutter‐Fibrillation After Myocardial Infarction
2005
Endotoxin, Toll-like receptor 4, and the afferent limb of innate immunity
2000 StandoutNobel
Physiology and Pathophysiology of Purinergic Neurotransmission
2007 Standout
Implantable Cardioverter Defibrillator Therapy in Children with Long QT Syndrome
2004
The Pathophysiology and Treatment of Sepsis
2003 Standout
Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: A case series and literature review
2012
Novel therapeutics for treatment of long-QT syndrome and torsade de pointes
2004
Skeletal muscle hypertrophy and anti‐atrophy effects of clenbuterol are mediated by the β2‐adrenergic receptor
2002 StandoutNobel
QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system
2005
Management of patients with palpitations: a position paper from the European Heart Rhythm Association
2011
Role of sodium and calcium channel block in unmasking the Brugada syndrome
2004
The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases
2014
Laboratory models of sepsis and septic shock
1990
Therapy for the Brugada Syndrome
2006
Brugada Syndrome
2002
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
1999 StandoutScience
Cardiovascular effects of Danshen
2007 Standout
Clinical and Genetic Heterogeneity of Right Bundle Branch Block and ST-Segment Elevation Syndrome
2000
The Brugada Syndrome
1998
Mapping and Ablation of Idiopathic Ventricular Fibrillation
2002
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy
2020 Standout
Muscle wasting associated with endotoxemia in the rat: Modification by the β2-adrenoceptor agonist clenbuterol
1989
Brugada Syndrome: Report of the Second Consensus Conference
2005 Standout
Electrical storms in Brugada syndrome: review of pharmacologic and ablative therapeutic options.
2005
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Contemporary Definitions and Classification of the Cardiomyopathies
2006 Standout
Cellular Basis for the Brugada Syndrome and Other Mechanisms of Arrhythmogenesis Associated With ST-Segment Elevation
1999
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Opioid Complications and Side Effects
2008 Standout
Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of [alpha]2B adrenoceptors.
2000 StandoutNobel
Endotoxemia associated with cardiopulmonary bypass
1987
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
2014 Standout
2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
2017
Works of Roman Fish being referenced
Ventricular Flutter Induced During Electrophysiologic Studies in Patients with Old Myocardial Infarction:
2003
Adenosine-5′-triphosphate test for the noninvasive diagnosis of concealed accessory pathway
2000
Effects of Electrophysiologic‐Guided Therapy with Class IA Antiarrhythmic Drugs on the Long‐Term Outcome of Patients with Idiopathic Ventricular Fibrillation with or without the Brugada Syndrome
1999
QT or Not QT?
2000
Rate smoothing with cardiac pacing for preventing torsade de pointes
2000
Mode of Onset of Malignant Ventricular Arrhythmias in Idiopathic Ventricular Fibrillation
1997
Pause-dependent torsade de pointes following acute myocardial infarction
2001
Prevention of ventricular arrhythmias in the congenital long QT syndrome
2000
Myocardial dysfunction in a nonlethal, nonshock model of chronic endotoxemia.
1985
Continuous infusion of endotoxin from an osmotic pump in the conscious, unrestrained rat: a unique model of chronic endotoxemia.
1984